463. Fusarium infections in a pediatric burn unit: A nine-year experience
Session: Poster Abstract Session: Mucor, Fusarium, and other Filamentous Mycoses
Thursday, October 8, 2015
Room: Poster Hall
Posters
  • fusarium para idsa 2015.pdf (1.2 MB)
  • Background: Fusarium species(spp) are ubiquitous fungi and with the prolonged survival of severely burned patients, fungal infections have become more common and Fusarium spp can produce severe infections in this population. The literature on  Fusarium spp infections in burn pediatric patients is scarce. Objective: To describe clinical and epidemiological features and outcome of  fusariosis in pediatric burn patients.  

    Methods: A retrospective, descriptive study of Fusarium spp infections in a specialized pediatric intensive care unit from January 2006 to March 2015

    Results: A total of 15 patients developed Fusarium spp infections. Median age of patients was 48 months (interquartile range, 12-108 months) and the affected burn surface was 45% (interquartile range, 30-60%). Twelve patients (80%) had a full thickness burn.

    The median time lapse between admission and fungal infection was 11 days (interquartile range, 4-24 days). The most frequent isolation site was the burn wound in 14 patients (93%) and bone in 1 patient (7%). In 13 patients (87%) bacterial infections were also found. Amphotericin B was the drug of choice followed by voriconazole. Median time of complete treatment was 23 days (interquartile range: 17-35 days). No drug-related adverse effects were reported. The combination of medical monotherapy with voriconazole or amphotericin B and surgery with removal of focal lesions was effective in all cases. None of the patients died of fungal-infection- related causes

    Conclusion: Fusarium spp is an uncommon pathogen in severely burned patients. The combination of medical monotherapy with voriconazole or amphotericin B and surgery was effective in such cases. None of the patients died.

    Maria Rosanova, MD-PhD1, Martin Brizuela, MD2, Mabel Villasboas, MD2, Fabian Quarracino, MD2, Veronica Alvarez, Nurse2, Griselda Berberian, MD3, Norma Sberna, Pharm2, Claudia Sarkis, MD4 and Patricia Santos, MD2, (1)Hospital De Pediatrķa Juan P. Garrahan, Buenos Aires, Argentina, (2)Hospital J P Garrahan, Buenos Aires, Argentina, (3)Epidemiology and Infectious Disease, Hospital de Pediatrķa Juan P. Garrahan, Buenos Aires, Argentina, (4)Hospital de pediatria JP Garrahan, Buenos Aires, Argentina

    Disclosures:

    M. Rosanova, None

    M. Brizuela, None

    M. Villasboas, None

    F. Quarracino, None

    V. Alvarez, None

    G. Berberian, None

    N. Sberna, None

    C. Sarkis, None

    P. Santos, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.